As do rates of lipid-lowering medication use.

Takeaway

• New-onset dyslipidaemia, including abnormal triglycerides and cholesterol requiring lipid-lowering medications, is a frequent postacute phase consequence of SARS-CoV-2 infection.
• This study adds to growing evidence that people who survive COVID-19 are at higher risk for cardiometabolic disorders.

Why this matters

• Disturbances to...